Nasdaq · Common stock
Latigo Biotherapeutics (LTGO)
$15.26 +$0.24 (+1.60%)
- Day’s range
- $14.24–$15.49
- Volume
- 165,323
LTGO price history
LTGO closed at $15.26 on Oct. 26, 2026. Over the past year, its daily close ranged from $14.00 on Oct. 14, 2026 to $25.00 on Aug. 27, 2026.
Data table: LTGO daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $15.26 |
| Oct. 23, 2026 | $15.02 |
| Oct. 22, 2026 | $16.57 |
| Oct. 21, 2026 | $16.34 |
| Oct. 20, 2026 | $15.25 |
| Oct. 19, 2026 | $14.30 |
| Oct. 16, 2026 | $14.00 |
| Oct. 15, 2026 | $14.76 |
| Oct. 14, 2026 | $14.00 |
| Oct. 13, 2026 | $15.71 |
| Oct. 12, 2026 | $16.02 |
| Oct. 9, 2026 | $16.00 |
| Oct. 8, 2026 | $14.79 |
| Oct. 7, 2026 | $15.52 |
| Oct. 6, 2026 | $16.26 |
| Oct. 5, 2026 | $16.63 |
| Oct. 2, 2026 | $15.90 |
| Oct. 1, 2026 | $16.69 |
| Sept. 30, 2026 | $16.70 |
| Sept. 29, 2026 | $18.10 |
| Sept. 28, 2026 | $17.48 |
| Sept. 25, 2026 | $17.15 |
| Sept. 24, 2026 | $17.76 |
| Sept. 23, 2026 | $19.97 |
| Sept. 22, 2026 | $20.82 |
| Sept. 21, 2026 | $21.11 |
| Sept. 18, 2026 | $22.55 |
| Sept. 17, 2026 | $23.93 |
| Sept. 16, 2026 | $23.06 |
| Sept. 15, 2026 | $23.01 |
| Sept. 14, 2026 | $22.64 |
| Sept. 11, 2026 | $22.15 |
| Sept. 10, 2026 | $21.54 |
| Sept. 9, 2026 | $22.80 |
| Sept. 8, 2026 | $23.73 |
| Sept. 4, 2026 | $23.04 |
| Sept. 3, 2026 | $22.48 |
| Sept. 2, 2026 | $21.77 |
| Sept. 1, 2026 | $22.26 |
| Aug. 31, 2026 | $22.02 |
| Aug. 28, 2026 | $24.23 |
| Aug. 27, 2026 | $25.00 |
| Aug. 26, 2026 | $24.13 |
| Aug. 25, 2026 | $22.57 |
| Aug. 24, 2026 | $22.00 |
| Aug. 21, 2026 | $22.37 |
| Aug. 20, 2026 | $21.40 |
| Aug. 19, 2026 | $20.94 |
| Aug. 18, 2026 | $20.00 |
| Aug. 17, 2026 | $19.30 |
| Aug. 14, 2026 | $19.49 |
| Aug. 13, 2026 | $20.06 |
| Aug. 12, 2026 | $19.38 |
| Aug. 11, 2026 | $18.52 |
| Aug. 10, 2026 | $18.56 |
| Aug. 7, 2026 | $18.25 |
Key figures
- Average daily volume
- 349,962Past 3 months
- Market value
- $1.01B
- Dividend yield
- —
Price change
- 1 month
- −11.02%
What Wall Street says about LTGO
In the past 90 days, Wall Street firms published 3 rating or price-target actions on LTGO: 3 new ratings.
| Action | Rating | |||
|---|---|---|---|---|
| Guggenheim | Initiates coverage | Buy | $50 | |
| Jefferies | Initiates coverage | Buy | $50 | |
| Leerink Partners | Initiates coverage | Outperform | $36 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
- Headquarters
- Thousand Oaks, Calif.
- Listed
- Aug. 7, 2026
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about LTGO is on the site yet.